A large study, conducted by Dr. James M. Brophy and his colleagues, from the McGill University Health Center in Montreal, confirms that selective COX2 inhibitors - Vioxx ( rofecoxib ) and Celebrex ( celecoxib ) are both associated with increased risk of repeat heart attack.大量的研究，所进行的博士詹姆斯米brophy和他的同事们，从麦吉尔大学健康中心在蒙特利尔，证实选择性cox2抑制剂-万络（罗非昔布）和西乐葆（塞来昔布）都是相关的风险增加，重复心脏病发作。 They also found that Vioxx (rofecoxib), but not Celebrex (celecoxib), is associated with increased risk of a first heart attack.他们还发现，万络（罗非昔布） ，但不希乐葆（塞来昔布） ，是相关的风险增加，一个首次心脏病发作。

While Vioxx was pulled from the US market due to an elevated risk of heart attacks and stroke in adults, Celebrex still remains on the US market.而万络撤出美国市场，由于风险升高心脏病发作和中风的成年人，西乐葆仍然是对美国市场。

They analyzed data on 125,000 patients, with an average age of 75, who were treated with an NSAID between January 1999 and June 2002.他们分析的数据， 125000患者，平均年龄75岁，谁治疗一非甾体抗炎药1999年1月至2002年6月。

The heart attack rate ratio with Vioxx use was 1.59 in patients with a prior heart attack and 1.23 in those without a previous heart attack.该心脏病发作率的比例与Vioxx的使用是1.59 ，在患者事先心脏病发作和1月23日在那些没有以前的心脏病发作。 The rate ratio with Celebrex was 1.40 for a repeat heart attack, but not significant for first-time heart attack.率的比例，与西乐葆是1.40一个重复心脏病发作，但不显着，为的第一次心脏病发作。

Source:资料来源：